Unsustainable blip

A report showing a 46% quarter over quarter rise in VC funding for biotech companies is just a blip on the screen. Despite the report's headline numbers, VCs think the real story still is the downward trend in both the number of firms focused on life sciences and the dollars they can raise from LPs.

But venture players also say this isn't necessarily bad, as it could improve the overall quality of VCs and focus more funding on fewer, but better, companies...